Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion

Cancer Immunology, Immunotherapy

Volumn 55, Issue 10, 2006, Pages 1219-1227

  Toh, Uhi ^a   Fujii, Teruhiko ^a   Seki, Naoko ^a   Niiya, Fumihiko ^a   Shirouzu, Kazuo ^a   Yamana, Hideaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunotherapy; Malignant pericardial effusion; Tumor infiltrating lymphocytes (TIL)

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CYTOTOXIC T LYMPHOCYTE; ENZYME RELEASE; ESOPHAGUS CANCER; FEMALE; FEVER; HEART TAMPONADE; HUMAN; INTERFERON PRODUCTION; LUNG CANCER; LYMPHOCYTE ACTIVATION; MALE; MALIGNANT PERICARDIAL EFFUSION; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDITIS; PRIORITY JOURNAL; TACHYCARDIA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION;

AGED; CARCINOEMBRYONIC ANTIGEN; CARDIAC TAMPONADE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASMS; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33745621880     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0112-8     Document Type: Article

References (36)

1. Press OW, Livingston R (1987) Management of malignant pericardial effusion and tamponade. JAMA 257:1088-1092
2. Vaitkus PT, Herrmann HC, LeWinter MM (1994) Treatment of malignant pericardial effusion. JAMA 272:59-64
3. Maher EA, Shepherd FA, Todd TJ (1996) Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 112:637-643
4. Girardi LN, Ginsberg RJ, Burt ME (1997) Pericardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusions. Ann Thorac Surg 64:1422-1427
5. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343:1122-1126
6. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K (2000) Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6:4663-4673
7. Ueda Y, Yamagishi H, Tanioka Y, Fujiwara H, Fujii N, Itoh T (1999) Clinical application of adoptive immunotherapy and IL-2 for treatment of advanced digestive tract cancer. Hepatogastroenterology 46:1274-1279
8. Toh U, Sudo T, Kido K, Matono S, Sasahara H, Mine T, Tanaka T, Sueyoshi S, Fujita H, Shirouzu K, Yamana H (2002) Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer. Int J Clin Oncol 7:372-375
9. Itoh K, Platsoucas CD, Balch CM (1988) Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168:1419-1441
10. Toh U, Yamana H, Nakao M, Imai Y, Takasu H, Fujita H, Shirouzu K, Itoh K (1997) HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. Cell Immunol 177:137-143
11. Chen YM, Yang WK, Ting CC, Tsai WY, Yang DM, Whang-Peng J, Perng RP (1997) Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 112:960-966
12. Nakao M, Yamana H, Imai Y, Toh Y, Toh U, Kimura A, Yamana H, Kakegawa T, Itoh K (1995) HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 55:4248-4252
13. Smith FE, Lane M, Hudgins PT (1974) Conservative management of malignant pericardial effusion. Cancer. 33(1):47-57
14. Cullinane CA, Paz IB, Smith D, Carter N, Grannis FW Jr (2004) Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 125:1328-1334
15. Morita T, Takiguchi Y, Tabeta H, Watanabe R, Kimura H, Kuriyama T (2000) Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 83:858-862
16. Martinoni A, Cipolla CM, Cardinale D, Civelli M, Lamanitia G, Colleoni M, Fiorentini C (2004) Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. Chest 126:1412-1416
17. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
18. Rosenberg SA, Lotze MT (1986) Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4:681-709
19. Topalian SL, Solomon D, Avis FP, Simpson AE, Freeksen DL, Lineham WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6:839-853
20. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Lineham WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484
21. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA (1996) Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 65:413-421
22. Topalian SL, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142:3714-3725
23. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F (2002) Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51(10):539-546
24. Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP (2002) Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 36(1):17-25
25. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 201(8):1257-1268
26. Toh U, Yamana H, Nakao M, Imai Y, Seki N, Takasu H, Kaneshige T, Fujita H, Shirouzu K, Itoh K (1997) HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. Cell Immunol 177(2):137-143
27. Ridolfi R, Flamini E, Riccobon A, De Paola F, Maltoni R, Gardini A, Ridolfi L, Medri L, Poletti G, Amadori D (1998) Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Cancer Immunol Immunother 51(10):539-546
28. Kass R, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD (2003) Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat 80(3):275-285
29. Aruga A, Shu S, Chang AE (1995) Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 41:317-324
30. + killer cells. Ann Hematol 74:51-56
31. Kjaergaard J, Hokland M, Nannmark U, Hokland P, Basse P (1998) Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand J Immunol 47:532-540
32. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH (1991) Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174:479-488
33. Basse PH, Nannmark U, Johansson BR, Herberman RB, Goldfarb RH (1991) Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 83:944-950
34. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD, Huhn D, Schmidt-Wolf IG (1998) Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 47:221-226
35. + T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer. Surgery 117:325-333
36. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676-1680